- MeSH
- Biomarkers * analysis MeSH
- Galectin 3 analysis metabolism standards MeSH
- Humans MeSH
- Natriuretic Peptides analysis metabolism MeSH
- Growth Differentiation Factor 15 analysis metabolism standards MeSH
- Heart Failure * diagnosis MeSH
- Troponin analysis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Galektin-3, člen rodiny solubilních neglykosylovaných lektinů, patří mezi novější biomarkery s prognostickou rolí u onemocnění srdce, ale také plic, ledvin, jater a dalších orgánů. Má prozánětlivé a profibrotické účinky, podílí se na patofyziologii rozvoje srdečního selhání. Existuje automatizovaná analytická metoda stanovení galektinu-3 s robustními analytickými znaky. Jsou známá referenční rozmezí i rozhodovací limity; v kardiologické literatuře panuje shoda o zvýšeném riziku horší prognózy podmíněné fibrózou a zánětem při koncentracích galektinu-3 nad 18 μg/L. Je známá biologická variabilita u zdravých osob i u pacientů, hodnoty koncentrací galektinu-3 jsou v čase stabilní. Nejvíce dat o galektinu-3 se týká kardiologické diagnostiky, patří mezi biomarkery s možným využitím u srdečního selhání, infarktu myokardu, transplantace srdce a dalších kardiologických jednotek, má také roli u dalších onemocnění. Vzhledem k připravované úhradě podle Seznamu výkonů a jeho diagnostickému a prognostickému potenciálu jde o biomarker vhodný pro použití v běžné klinické praxi.
Galectin-3, a member of the family of soluble non-glycosylated lectins, is a newer biomarker with a prognostic role in heart, lung, kidney, liver, and other organ diseases. Galectin-3 has proinflammatory and profibrotic effects and is involved in the pathophysiology of the development of heart failure. An automated analytical method with robust analytical characteristics is available, and reference intervals and decision limits are known. There is a consensus in the cardiology literature for an increased risk of worse prognosis due to fibrosis and inflammation at galectin-3 concentrations above 18 μg/L. Biological variation is known both in healthy subjects and patients with heart diseases and galectin-3 concentrations are stable over time. Most data on galectin-3 available in the literature relate to cardiac disease diagnostics - it belongs among the biomarkers with possible use mainly in heart failure, myocardial infarction, and heart transplantation. Due to the planned reimbursement by health insurance companies and its diagnostic and prognostic potential, galectin-3 seems to be a biomarker suitable for use in routine clinical practice.
- Keywords
- biologická variabilita, rozhodovací meze, analytické znaky,
- MeSH
- Biomarkers * MeSH
- Galectin 3 * analysis MeSH
- Humans MeSH
- Reference Values MeSH
- Heart Failure diagnosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Galektin-3 se v kardiologii používá především jako prognostický biomarker, jehož patofyziologické efekty souvisejí s rizikem fibrotizace a remodelace myokardu. Zvýšené koncentrace galektinu-3 v plazmě (obvykle nad rozhodovací mez 18 μg/L) znamenají riziko vyšší kardiovaskulární i celkové mortality především u pacientů se srdečním selháním, u pacientů po infarktu myokardu, po transplantaci srdce a u dalších kardiologických onemocnění. Výpovědní hodnota galektinu-3 se zvyšuje při kombinaci s natriuretickými peptidy. Galektin-3 v kardiologii představuje kandidátní molekulu pro odhad prognózy pacientů.
Galectin-3 is mainly used in cardiology as a prognostic marker. Its pathophysiological effects correlate with the risk of cardiac fibrosis and remodelation. Elevated concentrations of galectin-3 in plasma (above the decision limit of 18 μg/L) increase the risk of cardiovascular morbidity and overall mortality, especially in patients with heart failure, myocardial infarction, heart transplantation and other cardiac diseases. The predictive value of galectin-3 increases when combined with natriuretic peptides. In cardiology, galectin-3 is recognized as a candidate molecule for prognostication.
- MeSH
- Biomarkers MeSH
- Galectin 3 * analysis blood MeSH
- Myocardial Infarction diagnosis MeSH
- Cardiovascular Diseases diagnosis MeSH
- Humans MeSH
- Heart Failure diagnosis MeSH
- Heart Transplantation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- Keywords
- klinická studie COACH, klinická studie PRIDE, klinická studie Maryland UMD H - 23258,
- MeSH
- Biomarkers * MeSH
- Heart Failure, Diastolic * diagnosis mortality MeSH
- Ventricular Dysfunction, Left * diagnosis mortality MeSH
- Fibrosis * MeSH
- Galectin 3 * analysis diagnostic use pharmacology secretion MeSH
- Clinical Trials as Topic * MeSH
- Meta-Analysis as Topic * MeSH
- Natriuretic Peptides * MeSH
- Pathology * MeSH
- Prognosis * MeSH
- Heart Failure * diagnosis mortality prevention & control MeSH
- Health Planning Guidelines * MeSH
- Patient Readmission * MeSH
- MeSH
- Adenoma classification pathology MeSH
- CD56 Antigen analysis MeSH
- Ki-67 Antigen analysis MeSH
- Galectin 3 analysis MeSH
- Immunohistochemistry MeSH
- Keratin-19 analysis MeSH
- Humans MeSH
- Carcinoma, Merkel Cell pathology MeSH
- Thyroid Neoplasms pathology MeSH
- Thyroid Gland pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Overall MeSH
Keratin 19 and nuclear reactivity to an endogenous lectin, galectin-1, represent a potential marker of epidermal stem cells. We detected expression of keratin 19 and nuclear binding sites for galectin-1 in adult cells migrating from the hair follicle, where cells expressing keratin 19 are located in the bulge region. The results were compared with the expression of both markers in cells adhering from suspension prepared from the interfollicular epidermis without keratin-19-positive cells and with nuclear binding sites for galectin-1. The results were compared with data from basal cell carcinomas. All cells were analyzed concerning size, as it is known that cell diameter influences the clonogenic potential of keratinocytes. The major result of this study is the observation of transient expression of keratin 19 and nuclear galectin-1 binding sites in originally negative interfollicular epidermal cells induced by adhesion. These cells were very small in size, similar to basal cells of the interfollicular epidermis or the bulge region of the hair follicle. The influence of the suspension regimen on beta1-integrin expression, cell diameter and growth was also monitored. A population of cells highly positive for beta1 integrin of the same diameter as keratin-19-positive cells insensitive to induction of terminal differentiation by lack of anchorage was characterized. Cells of the same size were also observed in the keratin-19-positive cells of basal cell carcinomas. In conclusion, the expression of poor levels of differentiation induced by cell adhesion is transient. Also, keratin 19 expression should not be exclusively regarded as a marker of stem cell activity.
- MeSH
- Integrin beta1 analysis MeSH
- Carcinoma, Basal Cell metabolism pathology MeSH
- Cell Adhesion MeSH
- Cell Culture Techniques MeSH
- Time Factors MeSH
- Epidermal Cells MeSH
- Epidermis chemistry MeSH
- Financing, Organized MeSH
- Galectin 1 analysis MeSH
- Galectin 3 analysis MeSH
- Keratinocytes cytology chemistry MeSH
- Keratins analysis MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Skin Neoplasms metabolism pathology MeSH
- Cell Movement MeSH
- Intermediate Filament Proteins analysis MeSH
- Hair Follicle cytology chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Comparative Study MeSH
